Tigecycline's Bioavailability Basics
Tigecycline, a glycylcycline antibiotic, has low absolute oral bioavailability of about 12-20% when administered orally due to poor solubility, low permeability, and significant first-pass metabolism in the gut and liver.[1] It is primarily given intravenously (IV) to achieve therapeutic plasma levels, with IV bioavailability effectively at 100%.
Role of Excipients in Formulation
Excipients in tigecycline formulations—such as mannitol (bulking agent), sodium metabisulfite (antioxidant), and hydrochloric acid (pH adjuster) in the IV lyophilized powder—stabilize the drug for injection but do not directly influence oral bioavailability.[2] These are optimized for IV use and solubility enhancement post-reconstitution. No oral formulation is approved, so excipients target parenteral stability rather than absorption.
Factors Limiting Oral Bioavailability
Tigecycline's oral absorption is hindered by:
- Physicochemical properties: Large molecular weight (585 Da), zwitterionic nature at physiological pH, and low aqueous solubility (BCS Class 4-like profile).
- Efflux transporters: High affinity for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in the intestine, pumping the drug back into the gut lumen.
- Metabolism: Extensive hepatic uptake via OATP1B1/1B3 transporters and CYP3A4-mediated oxidation.
Excipients like surfactants (e.g., polysorbate 80) or cyclodextrins could theoretically inhibit efflux or improve solubility in experimental oral prototypes, boosting bioavailability to 30-50% in animal models, but human data is lacking.[3][4]
Impact of Specific Excipients on Absorption
- Solubilizers/cyclodextrins: Hydroxypropyl-β-cyclodextrin complexes increase tigecycline solubility 10-fold in vitro, potentially raising oral exposure by reducing precipitation in the gut. Rat studies show 2-3x higher AUC with cyclodextrin.[3]
- P-gp inhibitors (e.g., Tween 80, PEG): These block efflux, improving permeability in Caco-2 cell models by 40-60%, but risk toxicity and inconsistent clinical translation.[4]
- Negative examples: High mannitol levels (as in IV form) can cause osmotic diarrhea if oral, further reducing absorption.
No excipient has overcome bioavailability barriers enough for commercial oral tigecycline.
Comparison to IV Dosing
IV tigecycline bypasses GI barriers, delivering Cmax of 0.6-0.9 mcg/mL after 100 mg dose, versus oral peaks <0.2 mcg/mL.[1][2] Excipients enable this IV reliability but highlight why oral routes fail without major reformulation.
Research on Excipient-Enhanced Oral Delivery
Preclinical efforts combine tigecycline with SNEDDS (self-nanoemulsifying systems using Labrafil/Tween) or SMEDDS, achieving 25-40% bioavailability in rodents via lymphatic uptake evasion.[5] Challenges include stability and scale-up; no Phase III trials reported.
[1] Tigecycline prescribing information, FDA label
[2] DrugBank: Tigecycline pharmacokinetics
[3] Eur J Pharm Sci. 2013: Cyclodextrin complexes for tigecycline solubility
[4] Int J Pharm. 2015: P-gp inhibition effects
[5] J Control Release. 2018: Nanoemulsions for oral glycylcyclines